Portal de Periódicos da CAPES

Low-level laser therapy for treatment of temporomandibular joint pain: a double-blind and placebo-controlled trial

2008; Elsevier BV; Volume: 105; Issue: 4 Linguagem: Inglês

10.1016/j.tripleo.2007.09.012

1528-395X

Rüdiger Emshoff, Renato Bösch, Eduard Pümpel, Harald Schöning, Heinrich Strobl,

Botulinum Toxin and Related Neurological Disorders

Objective The objective of this study was to assess the effectiveness of low-level laser therapy (LLLT) in the management of temporomandibular joint (TMJ) pain in a random and double-blind research design. Study design TMJ pain patients, randomly assigned, received 2 to 3 treatments per week for 8 weeks of active LLLT (Helium Neon, 632.8 nm, 30 mW) (n = 26) or sham LLLT (n = 26). Measures of TMJ pain during function were evaluated at baseline and weeks 2, 4, and 8 after the first laser therapy. Results At the 8-week point, within-group improvements were present for TMJ pain during function, for both the active and sham LLLT groups (P = .000). Between-group differences were not highly evident (P > .05). Conclusion The study suggests that LLLT is not better than placebo at reducing TMJ pain during function. The objective of this study was to assess the effectiveness of low-level laser therapy (LLLT) in the management of temporomandibular joint (TMJ) pain in a random and double-blind research design. TMJ pain patients, randomly assigned, received 2 to 3 treatments per week for 8 weeks of active LLLT (Helium Neon, 632.8 nm, 30 mW) (n = 26) or sham LLLT (n = 26). Measures of TMJ pain during function were evaluated at baseline and weeks 2, 4, and 8 after the first laser therapy. At the 8-week point, within-group improvements were present for TMJ pain during function, for both the active and sham LLLT groups (P = .000). Between-group differences were not highly evident (P > .05). The study suggests that LLLT is not better than placebo at reducing TMJ pain during function.